Keros Therapeutics KROS Balance Sheet (2019-2026)

NASDAQ KROS
$11.10 -0.21 (-1.85%)
As of: Sep 10, 2026 · 1:27 PM EDT
Reported Financials

Keros Therapeutics Quarterly Balance Sheet

Periods 29 quarters
Latest Jun 2026

Keros Therapeutics reported total assets of $287.60M and total liabilities of $25.28M for the quarter ended Jun 2026, down 63.3% year over year. This balance sheet covers 29 quarters of results from Mar 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Balance Sheet Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Jun2026
Assets
Current Assets
Cash & EquivalentsCash & Equiv.
237.11M221.35M230.04M228.59M215.62M239.43M279.05M351.43M322.03M287.89M331.15M442.44M405.86M530.68M559.93M720.54M690.22M693.47M287.42M257.61M
Cash & Current Investments
237.11M221.35M230.04M228.59M215.62M239.43M279.05M351.43M322.03M287.89M331.15M442.44M405.86M530.68M559.93M720.54M690.22M693.47M287.42M257.61M
Receivables - NetNet Receivables
0.10M18.00M0.14M0.23M0.00M0.39M2.74M17.29M15.82M3.49M3.57M
Receivables - OtherOther Receivables
Receivables
0.10M18.00M0.14M0.23M0.00M0.39M2.74M17.29M15.82M3.49M3.57M
Prepaid Assets
4.20M4.72M3.40M2.63M6.74M6.45M6.72M10.79M12.28M16.54M16.00M20.46M26.85M20.97M26.22M21.68M26.78M22.34M22.20M7.03M
Current Assets
241.42M226.07M251.44M231.22M222.36M245.88M285.77M362.22M334.31M304.44M347.29M463.13M432.71M552.05M588.89M759.51M732.81M719.31M315.43M266.88M
Non-Current Assets
Property, Plant & Equipment (Net)PP&E (Net)
1.25M1.29M1.33M1.46M1.65M1.68M2.02M2.93M3.09M3.36M4.13M4.43M4.29M4.37M4.24M4.47M4.84M4.56M4.30M3.71M
Other Non-Current Assets
0.12M1.33M1.33M1.33M1.33M1.33M1.33M1.33M1.33M1.21M2.05M1.21M1.21M1.45M2.06M1.45M1.45M1.45M1.45M1.45M
Non-Current Assets
2.04M3.89M3.81M3.92M4.30M6.67M21.01M22.21M22.00M21.81M22.73M22.69M22.31M27.23M26.99M25.05M24.36M23.48M22.59M20.72M
Assets
243.46M229.96M255.25M235.14M226.66M252.55M306.78M384.44M356.31M326.25M370.02M485.82M455.02M579.27M615.89M784.56M757.16M742.78M338.02M287.60M
Liabilities
Current Liabilities
Accounts Payables
1.37M2.81M3.65M3.06M7.66M2.65M3.34M4.68M4.15M3.87M5.45M4.99M6.54M4.98M4.60M6.64M5.27M2.30M1.97M1.82M
Payables
1.37M2.81M3.65M3.06M7.66M2.65M3.34M4.68M4.15M3.87M5.45M4.99M6.54M4.98M4.60M6.64M5.27M2.30M1.97M1.82M
Accumulated Expenses
5.71M7.36M7.34M7.70M7.12M8.41M12.75M10.78M11.95M12.22M17.92M12.68M13.61M22.17M20.87M17.29M19.96M15.17M16.04M7.74M
Current Leases
0.45M0.84M0.86M0.88M0.67M0.46M0.46M0.61M1.00M1.05M1.10M1.86M1.98M2.10M2.23M2.32M2.41M2.60M
Current Taxes
10.04M6.32M4.15M
Current Deferred Revenue
3.31M0.93M0.15M
Total Current Liabilities
7.53M11.02M11.85M11.65M15.45M11.53M16.55M15.46M16.09M16.70M24.37M18.72M21.25M29.01M27.45M39.38M34.71M24.09M20.41M12.15M
Non-Current Liabilities
Preferred Stock Liabilities
Operating Leases
0.24M1.30M0.23M12.81M13.99M13.95M14.31M13.44M13.15M12.86M19.29M16.88M16.31M15.72M15.11M14.47M13.13M
Other Non-Current Liabilities
0.03M0.02M
Total Non-Current Liabilities
7.77M11.47M12.08M
Total Liabilities
7.80M11.48M12.08M11.65M15.45M11.53M29.36M29.45M30.05M30.41M37.81M31.87M34.11M46.44M44.33M55.69M50.43M39.20M34.89M25.28M
Shareholder's Equity
Common Equity
235.66M218.48M243.17M223.49M211.21M241.03M277.42M354.98M326.26M295.84M332.21M453.95M420.92M532.84M571.55M728.87M706.73M703.58M303.13M262.32M
Liabilities and Shareholders Equity
243.46M229.96M255.25M235.14M226.66M252.55M306.78M384.44M356.31M326.25M370.02M485.82M455.02M579.27M615.89M784.56M757.16M742.78M338.02M287.60M
Treasury Shares
21.13M21.13M
Retained Earnings
332.17M335.29M366.93M371.43M386.41M439.74M505.86M619.22M628.00M637.02M713.64M878.48M890.71M1,055.58M1,140.33M1,149.19M1,157.75M1,161.88M1,169.45M1,181.06M